Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OncoSil Medical Ltd ( (AU:OSL) ) has provided an update.
OncoSil Medical Ltd has released a prospectus for a fully underwritten, non-renounceable pro-rata entitlement offer to raise up to approximately $2 million before costs, issuing one new share for every 6.4 shares held at $0.68 per share, with one new option attached to each new share. The capital raising structure also includes additional option offers to certain placement investors and to the lead manager, Bell Potter Securities, underscoring the company’s need for new funding while highlighting the speculative nature of the investment and the standard legal and risk disclaimers typical of such offers.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is an ASX-listed medical company developing oncology-related technologies and treatments, positioned within the broader healthcare and biotech sector. The company targets investors familiar with speculative, early-stage medical ventures and operates under Australia’s continuous disclosure regime as a disclosing entity on the ASX.
Average Trading Volume: 24,813
Technical Sentiment Signal: Sell
Current Market Cap: A$15.11M
For an in-depth examination of OSL stock, go to TipRanks’ Overview page.